Development and Validation of a Novel Signature to Predict Overall Survival in “Driver Gene–negative” Lung Adenocarcinoma (LUAD): Results of a Multicenter Study

Abstract excerpt

Abstract Purpose: Examining the role of developmental signaling pathways in “driver gene–negative” lung adenocarcinoma (patients with lung adenocarcinoma negative for EGFR, KRAS, BRAF, HER2, MET, ALK, RET, and ROS1 were identified as “driver gene–negative”) may shed light on the clinical research and treatment for this lung adenocarcinoma subgroup. We aimed to investigate whether developmental signaling pathways...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Gene expression and cancer classification
• Share to Lung Cancer Diagnosis and Treatment
• Share to Lung Cancer Treatments and Mutations